Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology
- PMID: 16305311
- DOI: 10.1089/adt.2005.3.543
Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology
Abstract
Kinase inhibitors are at the forefront of modern drug research, where mostly three technologies are used for hit-and-lead finding: high throughput screening of random libraries, three-dimensional structure-based drug design based on X-ray data, and focused libraries around limited number of new cores. Our novel Nested Chemical Library (NCL) (Vichem Chemie Research Ltd., Budapest, Hungary) technology is based on a knowledge base approach, where focused libraries around selected cores are used to generate pharmacophore models. NCL was designed on the platform of a diverse kinase inhibitory library organized around 97 core structures. We have established a unique, proprietary kinase inhibitory chemistry around these core structures with small focused sublibraries around each core. All the compounds in our NCL library are stored in a big unified Structured Query Language database along with their measured and calculated physicochemical and ADME/toxicity (ADMET) properties, together with thousands of molecular descriptors calculated for each compound. Biochemical kinase inhibitory assays on selected, cloned kinase enzymes for a few hundred NCL compound sets can provide sufficient biological data for rational computerized design of new analogues, based on our pharmacophore model-generating 3DNET4W QSPAR (quantitative structure-property/activity relationships) approach. Using this pharmacophore modeling approach and the ADMET filters, we can preselect synthesizable compounds for hit-and-lead optimization. Starting from this point and integrating the information from QSPAR, high-quality leads can be generated within a small number of optimization cycles. Applying NCL technology we have developed lead compounds for several validated kinase targets.
Similar articles
-
Lessons learnt from assembling screening libraries for drug discovery for neglected diseases.ChemMedChem. 2008 Mar;3(3):435-44. doi: 10.1002/cmdc.200700139. ChemMedChem. 2008. PMID: 18064617 Free PMC article.
-
Chemical feature-based pharmacophores and virtual library screening for discovery of new leads.Curr Opin Drug Discov Devel. 2003 May;6(3):370-6. Curr Opin Drug Discov Devel. 2003. PMID: 12833670 Review.
-
The synergy between combinatorial chemistry and high-throughput screening.Curr Opin Drug Discov Devel. 2008 May;11(3):346-55. Curr Opin Drug Discov Devel. 2008. PMID: 18428088 Review.
-
Basic overview of chemoinformatics.J Chem Inf Model. 2006 Nov-Dec;46(6):2267-77. doi: 10.1021/ci600234z. J Chem Inf Model. 2006. PMID: 17125169 Review.
-
A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases.J Comb Chem. 1999 Jan;1(1):55-68. doi: 10.1021/cc9800071. J Comb Chem. 1999. PMID: 10746014
Cited by
-
Targeted drug combination therapy design based on driver genes.Oncotarget. 2019 Sep 3;10(51):5255-5266. doi: 10.18632/oncotarget.26985. eCollection 2019 Sep 3. Oncotarget. 2019. PMID: 31523388 Free PMC article.
-
Targeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitro.PLoS One. 2015 Apr 14;10(4):e0124234. doi: 10.1371/journal.pone.0124234. eCollection 2015. PLoS One. 2015. PMID: 25874616 Free PMC article.
-
Integrating molecular diagnostics into anticancer drug discovery.Nat Rev Drug Discov. 2010 Jul;9(7):523-35. doi: 10.1038/nrd3135. Epub 2010 Jun 7. Nat Rev Drug Discov. 2010. PMID: 20531274
-
MBC and ECBL libraries: outstanding tools for drug discovery.Front Pharmacol. 2023 Aug 11;14:1244317. doi: 10.3389/fphar.2023.1244317. eCollection 2023. Front Pharmacol. 2023. PMID: 37637414 Free PMC article.
-
Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters.PLoS One. 2018 Sep 5;13(9):e0202749. doi: 10.1371/journal.pone.0202749. eCollection 2018. PLoS One. 2018. PMID: 30183750 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous